Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using ultrasound to treat alcohol use disorder

Official title: Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

Run by University of California, San Francisco · NCT06518785 · Data updated 2026-11-12

This study is testing if using low-intensity ultrasound can help change brain activity in people with alcohol use disorder.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment25 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedJanuary 7, 2025
Main results expectedSeptember 2030
Study endsSeptember 2030
Registry record updatedSeptember 11, 2026
Trial IDNCT06518785 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older who have a documented diagnosis of alcohol use disorder.

Probably not a fit

Patients who are pregnant, have significant cognitive impairment, or are currently undergoing other investigational treatments for alcohol use disorder may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the effects of Low-Intensity Focused Ultrasound (LIFU) on brain activity in individuals with alcohol use disorder. It is a single-center, double-blind, controlled, randomized, complete block, 2-period crossover pilot trial. The research will assess how LIFU engages the ventral striatum by utilizing resting state and task-based functional magnetic resonance imaging (fMRI) to measure brain activity changes in response to the treatment.

Why it matters

Potential benefit: If successful, this approach could provide a non-invasive treatment option for individuals struggling with alcohol use disorder.

How similar studies have gone: While the use of ultrasound for neuromodulation is a novel approach, similar studies have shown promise in other neurological conditions, indicating potential for success in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female ≥ 18 years of age.
2. Documentation of an AUD diagnosis per DSM-5 criteria as evidenced by problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the DSM-5 criteria, occurring within a 12-month period.
3. Be willing to undergo a brain MRI and follow study protocol.

Exclusion Criteria:

1. Pregnant or breastfeeding.
2. Presence of a condition or abnormality that would compromise the safety of the patient or the quality of the data.
3. Non-English speaking.
4. Other investigational AUD treatments.
5. Primary psychosis, Bipolar I, or severe personality disorder.
6. Active suicidality or history of suicide attempt in the past 5 years.
7. Cognitive impairment (MoCA \<24)
8. Significant medical or neurological disease, or life expectancy \<12 mos.
9. Significant brain abnormality on brain imaging.
10. Any MRI exclusion criteria.

Where it's running

  • University of California, San Francisco
    San Francisco, California, United States
    Recruiting

Study contacts

  • Principal investigator: Khaled Moussawi, MD, PhD — University of California, San Francisco
  • Study coordinator: Catherine Borror, BS, CCRP
  • Email: TN2Lab@ucsf.edu
  • Phone: 415-514-6551

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.